Hyderabad: A commemorative stamp launched in honour of Covaxin and Indian Council of Medical Research (ICMR) would serve as an inspiration to young scientists, said Bharat Biotech, on Monday. "The commemorative stamp in honour of COVAXIN will serve as an inspiration and message to young scientists, innovators and entrepreneurs that if you have the skills and are willing to work hard, you can make it happen in India," the firm said in a tweet.
"India has been able to achieve the milestone of administering over 156 crore doses despite such a huge population and diversity. On the occasion of completion of one year of the Covid vaccination drive, a postage stamp has been released on the vaccine indigenously developed jointly by the ICMR and Bharat Biotech, realising Prime Minister Narendra Modi ji's dream of self-reliant India," Union Health Minister Mansukh Mandaviya said while launching the stamp.
-
#COVAXIN #Covaxin4Kids #BharatBiotech #1YearOfVaccineDrive #COVID19 #COVID pic.twitter.com/jSlnstDqWs
— BharatBiotech (@BharatBiotech) January 17, 2022 " class="align-text-top noRightClick twitterSection" data="
">#COVAXIN #Covaxin4Kids #BharatBiotech #1YearOfVaccineDrive #COVID19 #COVID pic.twitter.com/jSlnstDqWs
— BharatBiotech (@BharatBiotech) January 17, 2022#COVAXIN #Covaxin4Kids #BharatBiotech #1YearOfVaccineDrive #COVID19 #COVID pic.twitter.com/jSlnstDqWs
— BharatBiotech (@BharatBiotech) January 17, 2022
Bharat Biotech has recently announced that its indigenously developed COVID-19 vaccine Coavaxin is now a universal vaccine for adults and children. It is pertinent to note that Covaxin has also announced that its booster dose has shown effective, with robust neutralising antibody responses against both Omicron and Delta variants of SARS-CoV-2 virus. The Hyderabad-based vaccine-maker had claimed that the booster dose showed 100 percent effective against the Delta variant and 90 percent against the Omicron variant.
In a statement, Bharat Biotech has said, "Results from a study conducted at Emory University demonstrating that sera from subjects who received a booster dose of Covaxin (BBV152) six months after getting a primary two-dose series of Covaxin, neutralized the SARS-CoV-2 Omicron and Delta variants."
It also mentioned that earlier studies demonstrated the neutralizing potential of Covaxin against SARS-CoV-2 Variants of Concern Alpha, Beta, Delta, Zeta and Kappa. The study will be published on the pre-print server, medRXiv, shortly.
Also read: Bharat Biotech seeks full marketing approval from DCGI for Covaxin